| Preoperative demographics | |
| Gender (female) | 21% (63/304) |
| Age (years) | 49.2 ± 9.0 |
| Age group | |
| <40 | 16% (47/304) |
| 40–49 | 25% (77/304) |
| 50–59 | 59% (180/304) |
| BSA (m2) | 1.91 ± 0.22 |
| Diabetes mellitus | 8% (23/304) |
| Hypertension | 29% (87/304) |
| Hypercholesterolaemia | 19% (58/304) |
| Preoperative creatinine (μmol/l) | 87.4 ± 20.6 |
| Smoker (current or past) | 47% (143/304) |
| COPD | 5% (15/304) |
| PVD | 3% (10/304) |
| Timing of operation (non-elective case) | 16% (50/304) |
| History of myocardial infarction | 2% (5/304) |
| LV dysfunction, EF < 40% | 15% (45/304) |
| NYHA, 3 or 4 | 44% (135/304) |
| Aortic disease (AR/AS/ASR) | |
| AR | 35% (107/304) |
| AS | 48% (146/304) |
| ASR | 16% (47/304) |
| Preoperative infective endocarditis | 10% (29/304) |
| Operative demographics | |
| Implanted Hancock II size (mm) | |
| 21 | 7% (21/304) |
| 23 | 22% (68/304) |
| 25 | 30% (90/304) |
| 27 | 28% (86/304) |
| 29 | 13% (39/304) |
| Calculated EOA (cm2) | 1.46 ± 0.77 |
| Calculated EOA index (cm2/m2) | 0.77 ± 0.09 |
| EOA index <0.80 cm2/m2 | 62% (187/301) |
| Concomitant CABG | 20% (62/304) |
| Concomitant Asc Ao replacement | 13% (38/304) |
| Ao enlargement | 20% (60/304) |
| CPB time (min) | 98.8 ± 43.9 |
| Ao clamp time (min) | 72.2 ± 27.6 |
| Preoperative demographics | |
| Gender (female) | 21% (63/304) |
| Age (years) | 49.2 ± 9.0 |
| Age group | |
| <40 | 16% (47/304) |
| 40–49 | 25% (77/304) |
| 50–59 | 59% (180/304) |
| BSA (m2) | 1.91 ± 0.22 |
| Diabetes mellitus | 8% (23/304) |
| Hypertension | 29% (87/304) |
| Hypercholesterolaemia | 19% (58/304) |
| Preoperative creatinine (μmol/l) | 87.4 ± 20.6 |
| Smoker (current or past) | 47% (143/304) |
| COPD | 5% (15/304) |
| PVD | 3% (10/304) |
| Timing of operation (non-elective case) | 16% (50/304) |
| History of myocardial infarction | 2% (5/304) |
| LV dysfunction, EF < 40% | 15% (45/304) |
| NYHA, 3 or 4 | 44% (135/304) |
| Aortic disease (AR/AS/ASR) | |
| AR | 35% (107/304) |
| AS | 48% (146/304) |
| ASR | 16% (47/304) |
| Preoperative infective endocarditis | 10% (29/304) |
| Operative demographics | |
| Implanted Hancock II size (mm) | |
| 21 | 7% (21/304) |
| 23 | 22% (68/304) |
| 25 | 30% (90/304) |
| 27 | 28% (86/304) |
| 29 | 13% (39/304) |
| Calculated EOA (cm2) | 1.46 ± 0.77 |
| Calculated EOA index (cm2/m2) | 0.77 ± 0.09 |
| EOA index <0.80 cm2/m2 | 62% (187/301) |
| Concomitant CABG | 20% (62/304) |
| Concomitant Asc Ao replacement | 13% (38/304) |
| Ao enlargement | 20% (60/304) |
| CPB time (min) | 98.8 ± 43.9 |
| Ao clamp time (min) | 72.2 ± 27.6 |
BSA: body surface area; COPD: chronic obstructive pulmonary disease; PVD: peripheral vessel disease; EF: ejection fraction; NYHA: New York Heart Association classification; AR: aortic regurgitation; AS: aortic stenosis; EOA: effective orifice area; Asc Ao: ascending aorta; CPB: cardiopulmonary bypass.
| Preoperative demographics | |
| Gender (female) | 21% (63/304) |
| Age (years) | 49.2 ± 9.0 |
| Age group | |
| <40 | 16% (47/304) |
| 40–49 | 25% (77/304) |
| 50–59 | 59% (180/304) |
| BSA (m2) | 1.91 ± 0.22 |
| Diabetes mellitus | 8% (23/304) |
| Hypertension | 29% (87/304) |
| Hypercholesterolaemia | 19% (58/304) |
| Preoperative creatinine (μmol/l) | 87.4 ± 20.6 |
| Smoker (current or past) | 47% (143/304) |
| COPD | 5% (15/304) |
| PVD | 3% (10/304) |
| Timing of operation (non-elective case) | 16% (50/304) |
| History of myocardial infarction | 2% (5/304) |
| LV dysfunction, EF < 40% | 15% (45/304) |
| NYHA, 3 or 4 | 44% (135/304) |
| Aortic disease (AR/AS/ASR) | |
| AR | 35% (107/304) |
| AS | 48% (146/304) |
| ASR | 16% (47/304) |
| Preoperative infective endocarditis | 10% (29/304) |
| Operative demographics | |
| Implanted Hancock II size (mm) | |
| 21 | 7% (21/304) |
| 23 | 22% (68/304) |
| 25 | 30% (90/304) |
| 27 | 28% (86/304) |
| 29 | 13% (39/304) |
| Calculated EOA (cm2) | 1.46 ± 0.77 |
| Calculated EOA index (cm2/m2) | 0.77 ± 0.09 |
| EOA index <0.80 cm2/m2 | 62% (187/301) |
| Concomitant CABG | 20% (62/304) |
| Concomitant Asc Ao replacement | 13% (38/304) |
| Ao enlargement | 20% (60/304) |
| CPB time (min) | 98.8 ± 43.9 |
| Ao clamp time (min) | 72.2 ± 27.6 |
| Preoperative demographics | |
| Gender (female) | 21% (63/304) |
| Age (years) | 49.2 ± 9.0 |
| Age group | |
| <40 | 16% (47/304) |
| 40–49 | 25% (77/304) |
| 50–59 | 59% (180/304) |
| BSA (m2) | 1.91 ± 0.22 |
| Diabetes mellitus | 8% (23/304) |
| Hypertension | 29% (87/304) |
| Hypercholesterolaemia | 19% (58/304) |
| Preoperative creatinine (μmol/l) | 87.4 ± 20.6 |
| Smoker (current or past) | 47% (143/304) |
| COPD | 5% (15/304) |
| PVD | 3% (10/304) |
| Timing of operation (non-elective case) | 16% (50/304) |
| History of myocardial infarction | 2% (5/304) |
| LV dysfunction, EF < 40% | 15% (45/304) |
| NYHA, 3 or 4 | 44% (135/304) |
| Aortic disease (AR/AS/ASR) | |
| AR | 35% (107/304) |
| AS | 48% (146/304) |
| ASR | 16% (47/304) |
| Preoperative infective endocarditis | 10% (29/304) |
| Operative demographics | |
| Implanted Hancock II size (mm) | |
| 21 | 7% (21/304) |
| 23 | 22% (68/304) |
| 25 | 30% (90/304) |
| 27 | 28% (86/304) |
| 29 | 13% (39/304) |
| Calculated EOA (cm2) | 1.46 ± 0.77 |
| Calculated EOA index (cm2/m2) | 0.77 ± 0.09 |
| EOA index <0.80 cm2/m2 | 62% (187/301) |
| Concomitant CABG | 20% (62/304) |
| Concomitant Asc Ao replacement | 13% (38/304) |
| Ao enlargement | 20% (60/304) |
| CPB time (min) | 98.8 ± 43.9 |
| Ao clamp time (min) | 72.2 ± 27.6 |
BSA: body surface area; COPD: chronic obstructive pulmonary disease; PVD: peripheral vessel disease; EF: ejection fraction; NYHA: New York Heart Association classification; AR: aortic regurgitation; AS: aortic stenosis; EOA: effective orifice area; Asc Ao: ascending aorta; CPB: cardiopulmonary bypass.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
